Biotech company may earn $1.4B in ophthalmology, respiratory therapy deal

U.S. biotech company Pieris Pharmaceuticals partnered with Roche subsidiary Genentech for $20 million up front and may be eligible to receive more than $1.4 billion in additional milestone payments, The Pharma Letter reported May 25.

Advertisement
By: Patsy Newitt

The deal will aim to help the companies discover and develop respiratory and ophthalmology therapies. 

Pieris shares rocketed by nearly 50 percent within three hours of the news of the deal dropping.

Pieris will be responsible for discovery research, and Genentech will be responsible for IND-enabling activities, clinical development and commercialization of those programs.

How health plans can close the execution gap in value-based care — A practical AI-driven approach

Recommended Live Webinar on Mar 31, 2026 11:00 AM - 12:00 PM CST

Advertisement

Next Up in Ophthalmology

  • Montana physician practice acquired 

    Southlake, Texas-based Retina Consultants of America has acquired Montana Retina Consultants, according to a Feb. 5 news release.  Bozeman-based Montana…

    By: Patsy Newitt

  • Louisiana ophthalmology practice acquired 

    Vision Innovation Partners acquired Ophthalmic Associates of Alexandria (Va.), according to a Feb. 2 press release. Founded in 2010, Ophthalmic…

    By: Patsy Newitt

  • American Board of Ophthalmology names CEO

    The American Board of Ophthalmology has appointed Steven Gedde, MD, as its next CEO.  Dr. Gedde is an ophthalmologist and…

    By: Cameron Cortigiano
Advertisement

Comments are closed.